Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Change in Accured Expenses (2020 - 2025)

Bolt Biotherapeutics' Change in Accured Expenses history spans 6 years, with the latest figure at -$1.9 million for Q3 2025.

  • For Q3 2025, Change in Accured Expenses fell 523.87% year-over-year to -$1.9 million; the TTM value through Sep 2025 reached -$7.9 million, down 695.49%, while the annual FY2024 figure was -$4.9 million, 43.07% down from the prior year.
  • Change in Accured Expenses for Q3 2025 was -$1.9 million at Bolt Biotherapeutics, down from -$840000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $5.6 million in Q3 2022 and bottomed at -$6.6 million in Q1 2023.
  • The 5-year median for Change in Accured Expenses is -$88000.0 (2021), against an average of -$215000.0.
  • The largest annual shift saw Change in Accured Expenses soared 4015.69% in 2021 before it crashed 2618.18% in 2022.
  • A 5-year view of Change in Accured Expenses shows it stood at -$549000.0 in 2021, then skyrocketed by 152.28% to $287000.0 in 2022, then surged by 313.94% to $1.2 million in 2023, then plummeted by 327.1% to -$2.7 million in 2024, then surged by 30.24% to -$1.9 million in 2025.
  • Per Business Quant, the three most recent readings for BOLT's Change in Accured Expenses are -$1.9 million (Q3 2025), -$840000.0 (Q2 2025), and -$2.5 million (Q1 2025).